



September 24, 2015

Alphatec's Less-Invasive Arsenal(TM) Cortical Bone Fixation System Successfully Used in Over 50 Patients

Arsenal CBx™ to Enter Full Commercial Launch by Year-end

Featured at NASS Booth #1147

CARLSBAD, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, announced today that the Company's Arsenal Cortical Bone Fixation system, Arsenal CBx, has successfully been used in over fifty patients during its limited market release, which began in the second quarter of 2015. The Arsenal CBx system provides surgeons with an alternative procedure to traditional pedicle screw placement, by utilizing a midline approach and cortical bone trajectory to achieve maximum fixation through a less-invasive procedure. The Company will be showcasing the Arsenal CBx implants and instrumentation, as well as its portfolio of products at the upcoming North American Spine Society (NASS) Annual Meeting being held at McCormick Place West, Chicago, Illinois, from October 14th - 16th, 2015. Alphatec Spine will be located in booth number 1147.

Brian T. Rose, M.D., a fellowship-trained orthopedic spine surgeon and board-certified orthopedic surgeon who provides a full range of both surgical and non-surgical spinal orthopedic care at Texoma Medical Center in Denison Texas, shares "CBX is a great extension of the Arsenal platform, allowing me greater flexibility and choice for fixation based on specific patient anatomies and needs. With Arsenal CBx I am able to surgically treat patients who have a larger body habitus or who are very muscular with a less-invasive approach that I believe will create better fixation and improved outcomes."

The Arsenal CBX system further extends the Arsenal spinal fixation platform and includes specialized implants and instrumentation for a less-invasive surgical approach that utilizes cortical bone fixation. This system provides surgeons with a number of benefits, including direct visualization and decompression access through a less-invasive incision, thereby requiring minimal tissue resection and decreased muscle retraction. The unique single/dual-zone thread-form of the Arsenal CBx screw is designed to maximize construct fixation in the cortical trajectory, resulting in greater pullout strength, which can be ideal for osteoporotic bone. Arsenal CBx is a compatible fixation option for both posterior lumbar interbody fusion (PLIF) and transforaminal lumbar interbody fusion (TLIF) applications, in addition to being a unique muscle-sparing approach to revision surgery. Built off of the Arsenal Spinal Fixation platform, the Arsenal CBx system provides many of the same features and benefits to enable procedural efficiency and simplicity, including ergonomically designed instrumentation and a wide array of implants to treat unique patient pathologies.

"We continue to advance our go-to-market product strategy forward with the launch of the Arsenal CBx system," said Jim Corbett, President and Chief Executive Officer of Alphatec Spine. "Arsenal CBx further differentiates the Arsenal platform and provides us with an opportunity to meet a broader set of surgeon needs where a cortical approach would be a better choice for enhanced patient outcomes. We have received very positive feedback on Arsenal CBx thus far and we are looking forward to the full commercial launch."

About Alphatec Spine

Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a global medical device company that designs, develops, manufactures and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company's mission is to improve lives by delivering advancements in spinal fusion technologies. The Company and its affiliates market products in the U.S. and internationally via a direct sales force and independent distributors.

Additional information can be found at www.alphatecspine.com.

About the North American Spine Society (NASS)

The North American Spine Society is a global multidisciplinary medical society that utilizes education, research and advocacy to foster the highest quality, ethical, value-based and evidence-based spine care for patients. The society is comprised of almost 9,000 members worldwide from disciplines including orthopedic surgery, neurosurgery, physical medicine and rehabilitation, pain management, physical/occupational therapy, anesthesiology, radiology and other health care professionals focused on the spine.

Additional information can be found at www.nassannualmeeting.org.

Forward Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include the Company's ability to achieve profitable growth; the Company's ability to achieve both domestic and international growth and future profitability. The words "believe," "will," "should," "expect," "intend," "estimate" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to; the uncertainty of success in developing new products or products currently in Alphatec Spine's pipeline within forecast timeframes, or at all, including without limitation the products discussed in this press release; failure to achieve acceptance of Alphatec Spine's products by the surgeon community, including without limitation the products discussed in this press release; Alphatec Spine's ability to develop and expand its U.S. and/or global revenues; continuation of favorable third party payor reimbursement for procedures performed using Alphatec Spine's products, including the products discussed in this press release; unanticipated expenses or liabilities or other adverse events affecting cash flow or Alphatec Spine's ability to successfully control its costs or achieve profitability; uncertainty of additional funding; Alphatec Spine's ability to compete with other competing products and with emerging new technologies; product liability exposure; an unsuccessful outcome in any material litigation in which the Company is a defendant; patent infringement claims and claims related to Alphatec Spine's intellectual property. Please refer to the risks detailed from time to time in Alphatec Spine's SEC reports, including its Annual Report Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form 8-K. Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

Investor/Media Contact:

Christine Zedelmayer
Investor Relations
Alphatec Spine, Inc.
(760) 494-6610
czedelmayer@alphatecspine.com